Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
02 mars 2020 08h45 HE
|
Unum Therapeutics Inc.
BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism Investigational...
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
29 janv. 2020 07h05 HE
|
Unum Therapeutics Inc.
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- ...
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
07 déc. 2019 14h45 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Investor Conference
15 nov. 2019 07h30 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics Reports Third Quarter 2019 Financial Results
12 nov. 2019 16h30 HE
|
Unum Therapeutics Inc.
- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE,...
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 nov. 2019 08h30 HE
|
Unum Therapeutics Inc.
- Unum’s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment - - BOXR1030 T cells co-express the GOT2...
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
04 nov. 2019 16h00 HE
|
Unum Therapeutics Inc.
- Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum’s goals are to more selectively target solid tumors with its ACTR platform candidates and improve T...
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
02 oct. 2019 07h05 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Industry Conferences in September
05 sept. 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming September Investor Conferences
26 août 2019 07h05 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...